CHOKSI.BO · BSE
CHOKSI ASIA LIMITED
₹219.95
-4.33% (-₹9.95)
Prev. close
₹229.9
Volume
1,203
As of
BSE · may be slightly delayed · 13:45 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About CHOKSI ASIA LIMITED
Choksi Asia Limited primarily engages in the manufacture and sale of photosensitized materials and other products for the healthcare industry in India. It sells X-Ray films, lead screens, chemicals, radiation shielding materials, X-Ray generator, radiography camera, radioactive Sources and trading of other related accessories. The company also provides X-ray films and chemicals, which include laser green, laser blue, and laser chemical products; X-ray accessories, comprising screens, cassettes, illuminators, and aprons; and laser NDT chemicals for processing industrial X-ray film. In addition, it trades in specialty x-ray films and medical equipment. The company was formerly known as Choksi Imaging Limited and changed its name to Choksi Asia Limited in April 2025. Choksi Asia Limited was incorporated in 1992 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Samir Kanubhai Choksi
Headquarters
Mumbai
Employees
12
Website
choksi-asia.comExchange
View on BSE ↗Key stats
Market cap
₹131.07 Cr
P/E ratio (TTM)
25.0
EPS (TTM)
₹9.18
Beta (1Y · daily vs NIFTY 50)
1.21
Beta (5Y · monthly vs NIFTY 50)
0.86
Shares float
1.46 L
EPS · quarter ended Jun 2026
₹1.69
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 7.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11.02 Cr | ₹2.02 Cr | ₹71.87 L | ₹15.58 Cr | ₹36.98 Cr | ₹49.28 Cr | |
| EBITDA | — | — | ₹-1.44 Cr | ₹2.08 Cr | ₹5.37 Cr | ₹8.19 Cr |
| ₹1.91 Cr | ₹-42.30 L | ₹-47.54 L | ₹1.39 Cr | ₹3.10 Cr | ₹5.33 Cr | |
| Diluted EPS | ₹4.89 | ₹-1.08 | ₹-1.22 | ₹2.43 | ₹5.44 | ₹9.36 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹18.05 Cr | ₹41.79 Cr | ₹47.18 Cr | ₹47.43 Cr | |
| — | — | — | ₹3.83 Cr | ₹4.77 Cr | ₹1.92 Cr | |
| Stockholders' equity | — | — | ₹15.52 Cr | ₹33.45 Cr | ₹36.88 Cr | ₹42.10 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-2.52 Cr | ₹2.68 Cr | ₹-2.87 Cr | ₹74.06 L | |
| Investing cash flow | — | — | ₹3.35 Cr | ₹1.52 Cr | ₹63.25 L | ₹8.21 L |
| — | — | ₹0 | ₹46.94 L | ₹-1.20 Cr | ₹-3.40 Cr | |
| Capital expenditure | — | — | ₹-60,000 | ₹-61,000 | ₹-82.63 L | ₹-1.09 Cr |
| End cash position | — | — | ₹4.14 Cr | ₹10.43 Cr | ₹7.00 Cr | ₹7.56 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| CHOKSI ASIA LIMITED | ₹127.93 Cr | ₹224.4 | 24.4 | 3.04 | 12.7% | 0.05 | +33.2% | +149.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
CHOKSI ASIA Standalone June 2026 Net Sales at Rs 9.22 crore, down 22.5% Y-o-Y
Moneycontrol.com · 1 month ago